Emmaus Life Sciences Reports Q3 2023 Financial Results

TORRANCE, Calif., Nov. 14, 2023 /PRNewswire/ — Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three and nine…

Click here to view original post